Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEK | Q02763 | 12/20 | 0.80 |
| ▸ | KDR | P35968 | 11/20 | 0.80 |
| ▸ | FLT1 | P17948 | 10/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | NR1I3 | Q14994 | 2/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4764578 | 1.00 | TEK (0.80) | TEKKDRFLT1KDM4ENPC1 | |
| SCHEMBL4767151 | 0.89 | TEK (0.67) | TEKKDRFLT1NR1I3NR1I2 | |
| SCHEMBL4774488 | 0.89 | TEK (1.00) | TEKKDRFLT1GRM4CHEK2 | |
| SCHEMBL4767144 | 0.89 | TEK (0.67) | TEKKDRFLT1NR1I3NR1I2 | |
| SCHEMBL4774486 | 0.89 | TEK (1.00) | TEKKDRFLT1GRM4CHEK2 | |
| SCHEMBL4774625 | 0.89 | TEK (0.80) | TEKKDRFLT1NR1I3GRM4 | |
| SCHEMBL4774631 | 0.89 | TEK (0.80) | TEKKDRFLT1NR1I3GRM4 | |
| SCHEMBL4764887 | 0.89 | TEK (1.00) | TEKKDRFLT1GRM4 | |
| SCHEMBL4764883 | 0.89 | TEK (1.00) | TEKKDRFLT1GRM4 | |
| SCHEMBL4770227 | 0.80 | TEK (1.00) | TEKKDRFLT1NR1I3NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575963-B1 | ANTI-ANGIOGENETIC THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2008-05-07 | — | — | EP | disclosed |
| US-20060069109-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069109-A1 | Therapeutic agents | TIE1, TEK, KDR | TEK 2/4885KDR 3/4885FLT1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.